Bayer: Science For A Better Life

United States of America

Neurology Information for Grant Submissions

Bayer Neurology Medical Affairs Department is interested in receiving and reviewing Grant Applications to support appropriate programs as described below.

Therapeutic Areas/Disease States:


Intended Audience:

  • Physicians (Neurologists / MS Specialists)
  • Nurses
  • Pharmacists
  • Patients / Caregivers
  • Managed Markets

Bayer Neurology Rationale for Educational Support:

Areas of interest based on referenced literature:

  • Vitamin D and MS
  • Adherence and Continuity of Care
  • Interferon Biomarkers
  • Treatment Guidelines
  • Long Term Outcomes (Survival and Benefit of Early Treatment)

Accredited Proposal Requirements:

The proposal must be compliant with standards and guidelines for commercial support (e.g., ACCME).

The proposal should include:

  • Needs Assessment
  • Educational Design and Rationale for Selection
  • Learning Objectives
  • Proposed Faculty
  • Participant Recruitment Plan
  • Outcomes Strategy/plan
  • Definition of Successful Program
  • Detailed Budget (must use the template available on the website)

Provider Justification

(1) Copy of most recent accreditation letter and status

(2) Samples of other programs in similar therapeutic areas


Applications/proposals which are submitted and determined to be complete are reviewed monthly.

Acceptance of a Bayer educational grant indicates that you will:

  • Reconcile grant funding within 60 days of completion of the educational program
  • Permit a Bayer Medical Affairs representative to audit live programs of at least $5000 (Bayer Compliance staff may also audit live programs and/or review the use of the grant)
  • Share activity data and outcomes metrics within 30 days of their availability

Literature/Data Referenced:

  1. Baumhackl U. The search for a balance between short and long-term treatment outcomes in multiple sclerosis. J Neurol. 2008 Mar;255 Suppl 1:75-83.
  2. Guyatt GH, Ferrans CE, Halyard MY, et al. Assessing quality of life in patients with multiple sclerosis. Int J MS Care. 2010;12:34-41.
  3. Guyatt GH, Ferrans CE, Halyard MY, et al. Assessing quality of life in patients with multiple sclerosis. Int J MS Care. 2010;12:34-41.
  4. Halper J, Perrin Ross A. Challenges in the treatment of mobility loss and walking impairment in multiple sclerosis. Int J MS Care. 2010;12:13-16.
  5. Harris VK, Sadiq SA. Disease Biomarkers in Multiple Sclerosis: Potential for Use in Therapeutic Decision Making. Molecular Diagnosis Ther. 2009;13:225-244.
  6. Kappos L, Freedman MS, Polman CH, et al. (2007). "Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study". Lancet 370 (9585): 389–97.
  7. Kieseier BC, Wiendl H, Hartung HP, Leussink VI, Stüve O. Risks and benefits of multiple sclerosis therapies: need for continual assessment?Curr Opin Neurol. 2011;24:238-243.
  8. Langdon DW, Amato MP, Boringa J, Brochet B, Foley F, Fredrikson S, Hämäläinen P, Hartung HP, Krupp L, Penner IK, Reder AT, Benedict RH. Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler. 2012 Jun;18(6):891-8. Epub 2011 Dec 21.
  9. Miller DM, Allen R. Quality of life in multiple sclerosis: determinants, measurement, and use in clinical practice. Curr Neurol Neurosci Rep. 2010;10:397-407
  10. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.. Ann Neurol. 2011;69:292-302.
  11. Saunders C, Caon C, Smrtka J, Shoemaker J. Factors that influence adherence and strategies to maintain adherence to injected therapies for patients with multiple sclerosis. J Neurosci Nurs.2010;42(5 Suppl):S10-8.